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Liver stiﬀness values in healthy subjects: Implications
for clinical practiceq
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Du Cane Road, London W12 0HS, UKSee Article, pages 606–613Liver stiﬀness measurement (LSM) using transient
elastography is considered a promising technique for
the assessment of severity of chronic liver disease, hav-
ing been shown in a number of disease settings to be cor-
related with the ﬁbrosis stage as assessed histologically
[1–4]. Although a number of studies have included
groups of subjects without evidence of ﬁbrosis histolog-
ically, none has examined the range of liver stiﬀness val-
ues in a cohort of healthy subjects. The paper by Roulot
and colleagues in this edition of the Journal examines a
large cohort of subjects with no evidence of liver disease
to establish estimates for normal values and to investi-
gate possible factors in the apparently normal popula-
tion, which may aﬀect the LSM [5].
In previously published multivariate analyses of
cohorts of patients with chronic liver disease, ﬁbrosis
was found to be the only factor to correlate signiﬁcantly
with increasing LSM [1,2,6]. However, the authors of
the original proof-of-principle in vitro study recognised
that a single physical parameter (i.e. stiﬀness) was unlikely0168-8278/$34.00  2008 European Association for the Study of the Liver.
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hepatic venous pressure gradient.to describe fully a complex biological system in which
ﬁbrosis is just one part [7]. Subsequent studies have dem-
onstrated that portal pressures, as assessed by the hepatic
venous pressure gradient (HVPG) [8] and inﬂammation,
as assessed by the histological necro-inﬂammatory grade
[9] also correlate with liver stiﬀness. Indeed, a paper by
Pinzani’s group has demonstrated an increase of LSM
in the cirrhotic range in patients with acute viral hepatitis
with no history of liver disease and, furthermore, reduc-
tion of liver stiﬀness, corresponding to biochemical
improvement of the hepatitis [10]. The eﬀect of steatosis
on LSM has not been investigated in depth, although his-
tological evidence of steatosis has not been found to aﬀect
liver stiﬀness on multivariate analysis of cohorts of
patients with chronic liver disease.
The knowledge that factors other than ﬁbrosis aﬀect
liver stiﬀness makes analysis of subjects in whom there
is no ﬁbrosis all the more relevant. Roulot and col-
leagues examined a cohort of apparently healthy indi-
viduals attending a free health check. This study has
considerable strengths. The population studied exceeded
400 subjects, making it by far the largest study of liver
stiﬀness in ‘‘normal” individuals. LSMs were acquired
according to published criteria, by a single operator
who was blinded to the clinical data. By taking a popu-
lation of subjects attending a health check, rigorous clin-
ical and biological data collection was attainable from
subjects, who could be classiﬁed as healthy on the basis
of exclusion of factors predisposing to, or associated
with, liver disease. In addition, the diagnosis of
metabolic syndrome used validated diagnostic criteria.Published by Elsevier B.V. All rights reserved.
530 J.F.L. Cobbold, S.D. Taylor-Robinson / Journal of Hepatology 48 (2008) 529–531However, imaging of the liver was not reported to
exclude structural abnormalities. In addition, assess-
ment of cardiovascular health (apart from the presence
of hypertension) and in particular, the presence of a
degree of congestive heart failure was not reported.
From a physiological perspective, congestive cardiac
failure causes hepatic venous congestion, which is likely
to cause an increase in LSM and, as such, may be a
highly relevant confounding factor in subjects with the
metabolic syndrome. In addition, as this was a free
health check, there may have been a selection bias in
that those subjects attending may have had symptoms,
which triggered attendance.
Using the 5th and 95th centiles from the non-obese
population, normal values were tentatively estimated
at between 3.3–7.8 kPa in women and 3.8–8.0 kPa in
men. This ﬁts with previous work in which the cut-oﬀ
value for signiﬁcant ﬁbrosis (FP 2) was considered to
be 8.8 kPa (1). It was also found that liver stiﬀness
was higher in men than in women, in obese subjects than
lean subjects, and in those with the metabolic syndrome,
compared to those without the metabolic syndrome. The
metabolic syndrome was diagnosed in 59 of 429 subjects
analysed. In these subjects, the liver stiﬀness was found
to be signiﬁcantly higher than in those without the met-
abolic syndrome, when accounting for age and sex.
Unsurprisingly, those with the condition were much
more likely to be obese than those without, although
on multivariate analysis accounting for body mass index
(BMI), the metabolic syndrome was still a major deter-
minant of higher liver stiﬀness values. Despite this diﬀer-
ence, 88% of those with the metabolic syndrome had
LSMs within the deﬁned normal range for those without
the condition. This implies that there may be no clear
role for LSM in the diagnosis of the metabolic syn-
drome. It also suggests that the normal ranges for
LSM may have to be shifted in diﬀerent disease popula-
tions and raises a general note of caution when inter-
preting individual LSM results in isolation. In 4 of the
7 subjects with the metabolic syndrome and
LSM > 8 kPa, liver biopsy was performed, demonstrat-
ing NASH with ﬁbrosis stage F2 and steatosis involving
<10% of the hepatocytes. This was said to support the
hypothesis that isolated steatosis does not increase liver
stiﬀness. It might be preferable to state that this infor-
mation does not disprove the hypothesis, as the eﬀect
of isolated steatosis on liver stiﬀness measurement has
not been tested speciﬁcally in a cohort stratiﬁed primar-
ily by degree of hepatic steatosis, for example by using
proton magnetic resonance spectroscopy [11].
Satisfactory LSM was not possible in a quarter of
obese individuals (BMI > 30 kg/m2) and in 88% of those
with a BMI > 40 kg/m2. These patients were, by neces-
sity, excluded from the study but would be likely to have
hepatic steatosis: their liver stiﬀness may diﬀer from the
remainder of the cohort. This is something that might beassessed by MR elastography [12,13], or by development
of diﬀerent probes designed for obese subjects.
This study brings forward substantially the knowl-
edge of liver stiﬀness values in the normal population,
which may form a basis for future clinical practice.
However, a number of issues warrant further investiga-
tion. In this study, the mean BMI of the population
studied was 25.6 kg/m2. If LSM increases with BMI,
as was asserted by Roulot and colleagues, the export-
ability of concrete normal ranges may not be universal.
For example, in the Dallas Heart study of over 2000
individuals, the mean BMI was >30 kg/m2 in a popula-
tion where the mean age was comparable [14]. In such a
population, the failure rate for data acquisition is likely
to be substantially higher than that reported here, and
the normal ranges may apply to a smaller proportion
of the population. The applicability of the technique in
these circumstances should be investigated further and
may entail modiﬁcation of transient elastography hard-
ware. In addition, racial diﬀerences have not been
reported. Distribution of body fat varies with race
[15,16], and this may aﬀect rates of successful LSM
acquisition with implications for the normal values used
in areas of high ethnic diversity.
The possibility of using LSM as a screening tool for
liver disease in the general population has also been
raised. The technique is certainly safe and acceptable to
patients, and is relatively cheap when used on a large
scale. However, the relationship between liver stiﬀness
and the pathogenesis of liver disease is still unclear. It is
not possible to explain conﬁdently the cause of a high
LSM, since the actual or potential eﬀects of haemody-
namic changes including portal hypertension [8], hepatic
inﬂammation [10,17], and steatosis have to be borne in
mind in addition to ﬁbrosis [2,4]. Nevertheless, LSMs
may serve as a trigger for further investigation, as a stiﬀ
liver is seldom found in the absence of any pathology.
The liver stiﬀness threshold to trigger further investiga-
tion is open to debate and should take into account the
demographics of the population to be screened, the likely
prevalence of the condition to be screened for, and the
acceptability of subsequent investigations, both to the
subject and from the perspective of resource allocation.
LSMmight be used as a screening tool in a subpopulation
at high risk of chronic liver disease, such as those of South
Asian origin living in the UK (where there may be poten-
tial NAFLD in those with the metabolic syndrome [18]),
or those with a history of intravenous drug usage, who
have a high risk of viral hepatitis. In such instances, the
normal ranges within these populations should be
assessed and deﬁned appropriately.
The paper by Roulot and colleagues represents the
ﬁrst reported large scale attempt to deﬁne the normal
range of liver-stiﬀness measurements and this will surely
form the basis of attempts to widen the usage of LSM
beyond those with pre-deﬁned chronic liver disease.
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require diﬀerent cut-oﬀ values for normal ranges and
isolated LSM values still need to be interpreted in indi-
vidual patients in the context of other tests.
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